📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 3 — Process Validation (TILA-278)

Document ID: M3-PV
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q

Process Validation — TILA-278

The process-validation strategy for TILA-278 — a recombinant humanized immunoglobulin G1 (IgG1) bispecific monoclonal antibody produced by fed-batch Chinese hamster ovary (CHO) mammalian cell culture and administered subcutaneously (SC) by Virtual Biopharma Inc. for the treatment of moderate-to-severe ulcerative colitis (UC) — follows a three-stage product-lifecycle approach: (Stage 1) process design, (Stage 2) process qualification, comprising facility/equipment/utility qualification and process performance qualification (PPQ) across consecutive commercial-scale batches, and (Stage 3) continued process verification. Critical process parameters (CPPs), key process parameters (KPPs), and in-process controls (IPCs) with proven acceptable ranges anchor the strategy, which is established under ICH Q8-Q11 (pharmaceutical development, quality risk management, pharmaceutical quality system, and drug-substance development and manufacture) together with the applicable FDA (Process Validation: General Principles and Practices) and EMA (Guideline on Process Validation for Finished Products / for the manufacture of biotechnology-derived active substances) process-validation guidance. Validation encompasses both the drug substance (DS; CHO cell culture and platform purification) and the sterile drug product (DP; formulation, aseptic fill/finish, and device assembly), with dedicated attention to the attributes unique to an obligate-heterodimeric bispecific — correct heavy-/light-chain pairing and control of mispaired product-related species — and to the adventitious-agent and viral-safety expectations of a mammalian-cell-derived biologic developed for licensure under 21 CFR Part 601.

1. Regulatory Basis and Scope

The validation program is designed to demonstrate, with a high degree of assurance, that the commercial process consistently produces DS and DP meeting their predefined critical quality attributes (CQAs) and specifications (3.2.S.4.1 / 3.2.P.5.1). The governing standards are ICH Q5A(R2) (viral safety of biotechnology products derived from cell lines of human or animal origin), ICH Q5C (stability of biotechnological/biological products), ICH Q5D (derivation and characterization of cell substrates), ICH Q5E (comparability following manufacturing changes), ICH Q6B (specifications), and ICH Q8(R2)/Q9(R1)/Q10/Q11 for the enhanced (quality-by-design, QbD) development and quality-system framework. Because TILA-278 exerts two independent pharmacologic activities from a single entity — TL1A (TNFSF15) antagonism, which dampens TH1/TH17-driven mucosal inflammation and intestinal fibrosis, and interleukin-22 receptor (IL-22R; the IL-22RA1/IL-10RB heterodimer) agonism, which drives epithelial regeneration and mucosal-barrier repair — the validation confirms not only conventional IgG1 process performance but also consistent delivery of both functional arms and of the correctly assembled bispecific heterodimer that co-locates them on one molecule.

The scope covers: (i) the DS process from working-cell-bank (WCB) thaw through frozen bulk DS; (ii) the DP process from DS thaw and pooling through formulation, sterilizing-grade filtration, aseptic fill into the primary container, and assembly/labeling of the prefilled-syringe (PFS) and autoinjector presentations; (iii) dedicated orthogonal-support studies (viral clearance, impurity clearance, in-process hold-time stability, chromatography-resin and membrane lifetime, aseptic-process/media-fill qualification, sterilizing-filter validation, container-closure integrity, extractables/leachables, and shipping validation); and (iv) the continued-process-verification (CPV) program that sustains the validated state across the commercial lifecycle.

2. Stage 1 — Process Design

2.1 Quality-by-design and risk assessment

Process design followed an enhanced QbD approach in which the CQAs identified in the control-strategy risk assessment (3.2.S / M3-CS) were traced to unit operations and process parameters. Structured quality risk-management tools (process-mapping, failure-mode-and-effects analysis [FMEA], and initial risk-ranking-and-filtering) scored each parameter for its potential impact on a CQA and for uncertainty, yielding the classification of parameters as CPPs (direct, demonstrated CQA impact within or near the operating range), KPPs (impact on process consistency/yield), and non-critical parameters. High-criticality CQAs driving the design space include the two potencies (TL1A neutralization and IL-22R agonism), correct-heterodimer content and mispaired/homodimer/half-antibody species, high-molecular-weight (HMW) aggregates, charge and N-glycan variants, and the process-related impurities host-cell protein (HCP), residual host-cell DNA, and leached Protein A.

2.2 Univariate and multivariate characterization

CPP–CQA relationships were characterized at qualified scale-down models using design-of-experiments (DoE). For the fed-batch production bioreactor, culture temperature, pH, dissolved oxygen, feed strategy, and the defined temperature/pH shift were studied for their effect on titre, charge-variant and N-glycan distribution (afucosylation, high-mannose), and aggregate content; the ~14-day culture and target harvest titre of ~4–5 g/L were established within the resulting proven acceptable ranges (PARs) and narrower normal operating ranges (NORs). For the purification train — Protein A affinity capture, low-pH viral inactivation, cation-exchange (CEX, bind–elute) and anion-exchange (AEX, flow-through) chromatography, mixed-mode/hydrophobic-interaction polishing, 20 nm nanofiltration, and ultrafiltration/diafiltration (UF/DF) — load challenge, gradient, pH/conductivity, and pool-collection criteria were characterized for their effect on aggregate, charge-variant, mispaired-species, HCP, DNA, and Protein A clearance. The polishing operations are designed with explicit selectivity for the format-specific product-related species (homodimers, half-antibody, and light-chain-mispaired molecules) that arise from the knobs-into-holes/CrossMab assembly, so that the ≥ 90% correct-heterodimer and ≤ 5% mispaired-species targets are met with margin.

2.3 Scale-down model qualification

The scale-down models used for characterization and for the viral-clearance and resin-lifetime studies were formally qualified against manufacturing-scale performance (input material quality, key output attributes, and step yields) so that data generated at small scale are representative of, and applicable to, the 2000 L commercial process. Qualification of these models is a prerequisite for the Stage 2 support studies described in Section 3.

3. Stage 2 — Process Qualification

3.1 Facility, equipment, and utility qualification

Prior to PPQ, the manufacturing facility, process equipment (single-use and stainless-steel systems), automation, and critical utilities (water-for-injection, clean steam, process gases, and controlled-environment areas) completed commissioning and qualification (installation, operational, and performance qualification; IQ/OQ/PQ). Cleaning validation established that shared/product-contact equipment is cleaned to validated residue limits, and computerized-system validation covered the process-control and data-integrity systems. Environmental-monitoring qualification and personnel-aseptic qualification support the sterile DP operations (Section 3.5).

3.2 Drug-substance process performance qualification (PPQ)

DS PPQ was executed on a minimum of three consecutive commercial-scale batches manufactured at the nominal 2000 L single-use production-bioreactor scale using the WCB, the platform purification train, and the defined control strategy, without deviation from the intended commercial process. A pre-approved PPQ protocol specified, for every unit operation, the CPP set points and ranges, the IPCs and their acceptance/action limits, sampling plans (including additional characterization sampling beyond routine release), and the batch-level and cross-batch acceptance criteria. Attributes qualified include viable-cell density/viability and titre trajectories; Protein A eluate pH and low-pH inactivation hold time/pH; chromatography pool volumes, product concentrations, and step yields; in-process aggregate and charge-variant IPCs at the polishing pools; nanofilter integrity; and final UF/DF pool concentration and pH. All PPQ batches met the batch-specific acceptance criteria and demonstrated inter-batch consistency for the CQAs, including both potencies, correct-heterodimer content, size and charge purity, N-glycan profile, and the process-related impurities. Representative confirmatory results for the qualification lot (DS-278-0011) are reported in the DS batch-analysis table (3.2.S.4.4) and are consistent with the toxicology and clinical lots. Maximum in-process hold times and pool storage conditions applied during PPQ were bounded by the hold-time stability studies of Section 3.6.

3.3 Viral clearance validation

Viral clearance was validated in the qualified scaled-down model per ICH Q5A(R2) using a panel of relevant and specific model viruses spanning enveloped/non-enveloped and RNA/DNA genomes, across the dedicated and contributory removal/inactivation steps (low-pH inactivation, AEX flow-through, and 20 nm nanofiltration; the Protein A step contribution was assessed separately). The orthogonal design combines an enveloped-virus inactivation mechanism (low pH) with two size/charge-based removal mechanisms (AEX, nanofiltration), providing robust clearance of both enveloped and non-enveloped viruses. Consistent with parvovirus resistance to low pH, no inactivation credit is claimed for MVM/Reo-3 at the low-pH step. Representative cumulative log-reduction values (LRV) are:

Process step	X-MuLV (enveloped, RNA)	PRV (enveloped, DNA)	MVM/MMV (non-enveloped, DNA)	Reo-3 (non-enveloped, RNA)
Low-pH inactivation	≥ 4.8	≥ 4.5	n/a	n/a
AEX (flow-through)	≥ 4.2	≥ 4.0	≥ 3.5	≥ 4.0
Nanofiltration (20 nm)	≥ 5.5	≥ 5.3	≥ 4.8	≥ 5.0
Cumulative LRV	≥ 14.5	≥ 13.8	≥ 8.3	≥ 9.0

The cumulative LRVs provide substantial safety margin relative to the theoretical particle burden of the cell substrate. Cell-substrate freedom from adventitious and endogenous agents (in vitro/in vivo adventitious-virus assays, transmission electron microscopy for retrovirus-like particles, and qPCR-based retrovirus quantitation) was established at the master- and working-cell-bank level per ICH Q5A(R2)/Q5D, and the end-of-production cells (at or beyond the limit of in vitro cell age) were tested to confirm no induction of adventitious agents. The facility/process adventitious-agent control strategy is detailed in Module 3.2.A.2.

3.4 Impurity-clearance validation

Clearance of process-related impurities was demonstrated across the purification train, by both routine PPQ pool testing and dedicated spiking/clearance studies at scale-down where warranted. HCP (anti-CHO process-specific qualified ELISA), residual host-cell DNA (CHO-specific qPCR), leached Protein A (immunoassay), and residual selection agent/media components (specific assay) are reduced to below the DS acceptance criteria with adequate margin at each PPQ batch: HCP to ≤ 100 ppm, leached Protein A to ≤ 20 ng/mg, and residual host-cell DNA to below the health-based clearance threshold at the maximum clinical dose. Clearance of product-related mispaired and aggregated species by the polishing and nanofiltration operations was likewise confirmed against the correct-heterodimer (≥ 90.0%) and HMW acceptance criteria.

3.5 Aseptic-process and sterility-assurance validation (drug product)

The sterile DP is a preservative-free SC solution filled into a single-use PFS and an autoinjector incorporating the same primary container. Sterility assurance was validated by:

• Aseptic process simulation (media fill). Media fills covering the qualified fill parameters, container sizes, line speeds, maximum permitted interventions, and worst-case durations were performed to qualify each filling line and shift pattern, with acceptance based on the current sterility-assurance expectation of no contaminated units (with defined investigation/action criteria), supported by continuous viable/non-viable environmental and personnel monitoring in the Grade A/B aseptic core.
• Sterilizing-grade filtration validation. The 0.22 µm sterilizing-grade filters were validated for bacterial retention (challenge with Brevundimonas diminuta at ≥ 10⁷ CFU/cm²) under actual-process fluid, time, pressure, and flow conditions, together with product-compatibility, extractables, adsorption, and integrity-test correlation; pre-use post-sterilization integrity testing (PUPSIT) and post-use integrity testing are applied on the line.
• Container-closure integrity (CCI). CCI of the filled/stoppered PFS was validated by a qualified deterministic method (e.g., headspace analysis / high-voltage leak detection) and is retained on stability in lieu of routine sterility testing, per the CCI-lifecycle approach.

DP PPQ qualified the formulation (DS thaw/pooling, excipient and polysorbate addition, mixing, and final concentration/adjustment), sterilizing filtration, aseptic fill, and device assembly across consecutive commercial-scale batches at the nominal 450 mg-per-device presentation, confirming fill-weight/volume control, deliverable dose, subvisible particulates, and device functional attributes within specification.

3.6 In-process hold times, resin/membrane lifetime, and shipping

Maximum in-process pool hold times and storage conditions (temperature and duration) for each intermediate were validated by hold-time (in-process stability) studies demonstrating no adverse change in product quality or bioburden/endotoxin over the claimed intervals; these bounds framed the PPQ execution. Chromatography-resin and UF/DF-membrane reuse was supported by concurrent/prospective lifetime studies (small-scale cycling with confirmation of carryover, clearance capability, product quality, and sanitization efficacy) establishing the validated maximum cycle counts. Frozen bulk DS transport (≤ −40 °C) and DP distribution, including permitted temperature excursions and, for DS, freeze/thaw cycling, were validated by shipping-qualification studies consistent with the stability data (3.2.S.7 / 3.2.P.8).

3.7 Extractables and leachables

An extractables/leachables program appropriate to a frozen protein DS (single-use bioprocess-container contact) and to the sterile SC DP (primary container-closure and device fluid path) was performed, with a leachables assessment over shelf life confirming that leached species remain below toxicological thresholds and do not adversely affect product quality (including aggregation and polysorbate integrity).

4. Stage 3 — Continued Process Verification

A CPV program maintains the validated state throughout the commercial lifecycle under the ICH Q10 pharmaceutical quality system. CPPs, KPPs, IPCs, and CQAs are trended on an ongoing basis using statistical process control (control charts and process-capability indices), with pre-defined alert/action rules that trigger investigation before a specification is at risk. The CPV plan defines the parameters monitored, sampling frequency, statistical methods, and periodic review cadence, and it feeds the Annual Product Review / Product Quality Review. Reference-standard continuity (two-tiered primary/working standards traceable to clinically qualified material) is maintained so that reported potency and purity do not drift across the lifecycle. Any signal, adverse trend, or confirmed out-of-specification result is managed through deviation, CAPA, and change-control processes, with re-qualification triggered where warranted.

5. Comparability and Clinical/Nonclinical Linkage

The evolution of the process from the early clinical/toxicology process to the commercial process is managed under an ICH Q5E comparability framework, using the release panel supplemented by extended physicochemical and functional characterization (higher-order structure, full glycan and charge-variant mapping, both binding functions, and forced degradation). The single relevant nonclinical toxicology species is the cynomolgus monkey, and the repeat-dose SC toxicology material (lot DS-278-0002) together with the clinical DS lots used to manufacture drug product for the pivotal Phase 2b induction study TILA278-201 (lots DS-278-0005 and DS-278-0006) were produced by qualified processes and shown to be comparable to the PPQ material at the level of physicochemical characterization, both potency assays, and product-/process-related impurity profiles. This comparability is the quality bridge that connects the validated commercial process to the exposure–response and safety experience established in TILA278-201, in which Week-12 clinical remission (modified Mayo ≤ 2, no subscore > 1) was dose-ordered at 37.3% (High), 16.2% (Low), and 0.7% (placebo), with modified-Mayo LS-mean changes of −3.36 (High), −2.76 (Low), and −1.00 (placebo). Because the delivered biological activity of each arm is directly linked to this clinical benefit, the validation program's assurance of consistent dual potency and correct bispecific assembly is central to the overall quality argument.

6. Conclusion

The lifecycle validation program demonstrates that the TILA-278 commercial process — CHO fed-batch production followed by Protein A capture and orthogonal polishing, with dedicated viral inactivation and removal, UF/DF, and aseptic SC fill/finish — is designed with defined CPPs and control strategy (Stage 1), qualified through facility qualification and PPQ across consecutive commercial-scale batches supported by validated viral and impurity clearance, aseptic-process/sterility-assurance, hold-time, lifetime, and container/shipping studies (Stage 2), and sustained by continued process verification (Stage 3). The distinguishing features are the explicit qualification of correct bispecific-heterodimer assembly and mispaired-species control, the two-mechanism potency assurance linking the validated process to the dose-ordered efficacy of TILA278-201, and adventitious-agent/viral safety consistent with ICH Q5A(R2). All qualified attribute levels bracket the ranges of the nonclinically and clinically qualified material, supporting the commercial process as validated and fit for its intended use under the applicable ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, and M4Q expectations.